![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPG21 |
Gene summary for SPG21 |
![]() |
Gene information | Species | Human | Gene symbol | SPG21 | Gene ID | 51324 |
Gene name | SPG21 abhydrolase domain containing, maspardin | |
Gene Alias | ABHD21 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0002253 | UniProtAcc | A0A024R5Y1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51324 | SPG21 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.65e-03 | 2.82e-01 | -0.1954 |
51324 | SPG21 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.08e-02 | 3.41e-01 | -0.059 |
51324 | SPG21 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.83e-02 | 2.96e-01 | 0.0674 |
51324 | SPG21 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.77e-10 | 5.22e-01 | 0.294 |
51324 | SPG21 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.94e-03 | 3.04e-01 | 0.281 |
51324 | SPG21 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.52e-04 | 3.19e-01 | 0.3859 |
51324 | SPG21 | A015-C-203 | Human | Colorectum | FAP | 1.02e-05 | -1.49e-01 | -0.1294 |
51324 | SPG21 | A001-C-108 | Human | Colorectum | FAP | 2.01e-04 | -1.36e-01 | -0.0272 |
51324 | SPG21 | A002-C-205 | Human | Colorectum | FAP | 3.24e-02 | -1.67e-01 | -0.1236 |
51324 | SPG21 | A015-C-104 | Human | Colorectum | FAP | 8.87e-08 | -1.92e-01 | -0.1899 |
51324 | SPG21 | A002-C-016 | Human | Colorectum | FAP | 2.09e-02 | -1.54e-01 | 0.0521 |
51324 | SPG21 | A002-C-116 | Human | Colorectum | FAP | 1.07e-05 | -1.72e-01 | -0.0452 |
51324 | SPG21 | LZE4T | Human | Esophagus | ESCC | 1.39e-09 | 1.24e-01 | 0.0811 |
51324 | SPG21 | LZE7T | Human | Esophagus | ESCC | 1.16e-04 | 4.52e-01 | 0.0667 |
51324 | SPG21 | LZE8T | Human | Esophagus | ESCC | 7.27e-05 | 7.56e-02 | 0.067 |
51324 | SPG21 | LZE20T | Human | Esophagus | ESCC | 4.88e-06 | 2.70e-01 | 0.0662 |
51324 | SPG21 | LZE22T | Human | Esophagus | ESCC | 3.53e-04 | 5.96e-01 | 0.068 |
51324 | SPG21 | LZE24T | Human | Esophagus | ESCC | 7.24e-28 | 9.00e-01 | 0.0596 |
51324 | SPG21 | LZE21T | Human | Esophagus | ESCC | 2.75e-04 | 3.08e-01 | 0.0655 |
51324 | SPG21 | P1T-E | Human | Esophagus | ESCC | 2.06e-06 | 7.35e-01 | 0.0875 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
GO:00022536 | Thyroid | HT | activation of immune response | 47/1272 | 375/18723 | 3.55e-05 | 7.40e-04 | 47 |
GO:00027648 | Thyroid | HT | immune response-regulating signaling pathway | 50/1272 | 468/18723 | 9.96e-04 | 1.02e-02 | 50 |
GO:00508515 | Thyroid | HT | antigen receptor-mediated signaling pathway | 27/1272 | 240/18723 | 6.87e-03 | 4.20e-02 | 27 |
GO:00024293 | Thyroid | HT | immune response-activating cell surface receptor signaling pathway | 31/1272 | 291/18723 | 8.69e-03 | 4.92e-02 | 31 |
GO:00027573 | Thyroid | HT | immune response-activating signal transduction | 31/1272 | 291/18723 | 8.69e-03 | 4.92e-02 | 31 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa041446 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
hsa041447 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa0414428 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
hsa0414436 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
hsa0414425 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
hsa04144111 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
hsa0414426 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
hsa0414435 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPG21 | SNV | Missense_Mutation | c.244T>C | p.Trp82Arg | p.W82R | Q9NZD8 | protein_coding | deleterious(0) | possibly_damaging(0.89) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPG21 | SNV | Missense_Mutation | c.596G>A | p.Arg199Lys | p.R199K | Q9NZD8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
SPG21 | SNV | Missense_Mutation | c.173N>G | p.Val58Gly | p.V58G | Q9NZD8 | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-CM-4746-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SPG21 | SNV | Missense_Mutation | rs756437687 | c.644N>A | p.Arg215Gln | p.R215Q | Q9NZD8 | protein_coding | tolerated(0.64) | benign(0.006) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR |
SPG21 | SNV | Missense_Mutation | c.499A>C | p.Asn167His | p.N167H | Q9NZD8 | protein_coding | deleterious(0.02) | possibly_damaging(0.63) | TCGA-CI-6620-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Ancillary | leucovorin | PD | |
SPG21 | insertion | Frame_Shift_Ins | c.487dupA | p.Ile163AsnfsTer17 | p.I163Nfs*17 | Q9NZD8 | protein_coding | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |||
SPG21 | deletion | Frame_Shift_Del | c.487delA | p.Ile163Ter | p.I163* | Q9NZD8 | protein_coding | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
SPG21 | SNV | Missense_Mutation | novel | c.320N>A | p.Gly107Asp | p.G107D | Q9NZD8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SPG21 | SNV | Missense_Mutation | c.760G>A | p.Gly254Ser | p.G254S | Q9NZD8 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
SPG21 | SNV | Missense_Mutation | rs755420818 | c.193N>A | p.Ala65Thr | p.A65T | Q9NZD8 | protein_coding | tolerated(0.22) | benign(0.015) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |